These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15791813)

  • 1. [Multiple myeloma--recent advances in diagnosis and treatment].
    Chou T
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):304-8. PubMed ID: 15791813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimising bortezomib in newly diagnosed multiple myeloma.
    Rajkumar SV
    Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of multiple myeloma: indications and options].
    Peest D; Ganser A
    Internist (Berl); 2007 Dec; 48(12):1343-8. PubMed ID: 17960351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches to the management of myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
    Palumbo A; Avonto I; Bruno B; Falcone A; Scalzulli PR; Ambrosini MT; Bringhen S; Gay F; Rus C; Cavallo F; Falco P; Massaia M; Musto P; Boccadoro M
    Clin Lymphoma Myeloma; 2006 May; 6(6):475-7. PubMed ID: 16796778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the treatment of multiple myeloma: a nursing perspective.
    Barrick M
    ONS News; 2006; 21(8 Suppl):15-6. PubMed ID: 16925133
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current therapy for multiple myeloma].
    Swieboda-Sadlej A
    Pol Arch Med Wewn; 2005 Oct; 114(4):1030-6. PubMed ID: 16789532
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
    Lok A; Mocquard J; Bourcier J; Redelsperger L; Bonnet A; Chauvin C; Thomaré P; Mahé B; Touzeau C; Moreau P
    Haematologica; 2014 Mar; 99(3):e33-4. PubMed ID: 24532044
    [No Abstract]   [Full Text] [Related]  

  • 11. [New strategy for the treatment of multiple myeloma].
    Murakami H
    Rinsho Ketsueki; 2005 Dec; 46(12):1263-72. PubMed ID: 16447798
    [No Abstract]   [Full Text] [Related]  

  • 12. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.
    Leleu X; Fouquet G; Hebraud B; Roussel M; Caillot D; Chrétien ML; Arnulf B; Szalat R; Garderet L; Benajiba L; Pegourie B; Regny C; Royer B; Caulier A; Stoppa AM; Garciaz S; Touzeau C; Chaleteix C; Fermand JP; Loiseau HA; Facon T; Attal M; Moreau P;
    Leukemia; 2013 Nov; 27(11):2242-4. PubMed ID: 23558525
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical management update: multiple myeloma.
    Stoopler ET; Vogl DT; Stadtmauer EA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 May; 103(5):599-609. PubMed ID: 17291793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Multiple myeloma--advances in disease biology and implications for therapy].
    Chou T
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1206-12. PubMed ID: 11579631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating novel therapies in the transplant paradigm.
    Harousseau JL
    Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 17. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ten years of improvement in the management of multiple myeloma: 2000-2010.
    Harousseau JL
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):424-42. PubMed ID: 21156460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapeutic strategy for multiple myeloma.
    Suzuki K
    Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
    Shuqing L; Jianmin Y; Chongmei H; Hui C; Wang J
    Exp Hematol; 2011 Dec; 39(12):1117-8. PubMed ID: 21920470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.